Literature DB >> 7511418

Effect of somatotropin and/or equine chorionic gonadotropin on serum and follicular insulin-like growth factor I and insulin-like growth factor binding proteins in cattle.

R L Stanko1, W S Cohick, D W Shaw, R W Harvey, D R Clemmons, M D Whitacre, J D Armstrong.   

Abstract

We investigated the effect of administration of somatotropin (ST) and/or eCG on insulin-like growth factor I (IGF-I) and IGF-binding proteins (IGFBP) in serum and follicular fluid (FFL) of cattle actively immunized against growth hormone-releasing factor (GRF). Cyclic beef cattle, previously immunized against GRF-(1-29)-Gly-Gly-Cys-NH2 conjugated to human serum albumin (synthesized and provided by Hoffmann-LaRoche, Inc., Nutley, NJ; GRFi, n = 31) or to human serum albumin alone (HSAi, n = 26), received (i.m.): 1) 25 mg recombinantly derived methionyl somatotropin (rbST, n = 14; sometribove provided by Monsanto Co., St. Louis, MO); 2) 1100 IU eCG (n = 10); 3) rbST and eCG (rbST-eCG, n = 15); or 4) vehicle (VEH, n = 17) at 0 and 24 h after receiving prostaglandin F2 alpha (PGF2 alpha). Serum samples were collected at 0 and 40 h after PGF2 alpha, and the ovary bearing the largest follicle (DOM) was removed 44.0 +/- 0.5 h after PGF2 alpha; FFL was harvested from DOM and the subordinate follicle (SUB). Before treatment (0 h), GRFi cows had lower serum ST (0.6 +/- 0.2 vs. 2.2 +/- 0.2 ng/ml; p < 0.01) and IGF-I (26 +/- 4 vs. 72 +/- 4 ng/ml; p < 0.01), but greater IGFBP-2 (594 +/- 48 vs. 384 +/- 52 ng/ml; p < 0.01) than HSAi cows. Serum and FFL concentrations of IGF-I or IGFBP-2 were not different between rbST- and rbST-eCG-treated cows or between VEH- and eCG-treated cows at Hour 40 after the initial treatment injection; therefore, data were combined and designated as rbST and VEH, respectively. Serum IGF-I was increased to a greater extent (percentage increase above 0 h) by rbST treatment in GRFi (362 +/- 24) than in HSAi (176 +/- 16) cows (immunization by treatment, p < 0.01). Across GRFi and HSAi, rbST lowered serum IGFBP-2 (342 +/- 31 vs. 541 +/- 27 ng/ml, rbST vs. VEH; p < 0.01). Diameters of DOM or SUB were not affected by immunization or treatment. Concentrations of IGF-I and IGFBP-3 (determined by ligand blot analysis) in FFL from both DOM and SUB were lower (p < 0.05) in GRFi than in HSAi cows. In contrast, IGFBP-2 in FFL was elevated in SUB, but not DOM, in GRFi compared to HSAi cows.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511418     DOI: 10.1095/biolreprod50.2.290

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  5 in total

1.  Estradiol and luteinizing hormone regulation of insulin-like growth factor binding protein production by bovine granulosa and thecal cells.

Authors:  Leon J Spicer; Connie S Chamberlain
Journal:  Endocrine       Date:  2002-04       Impact factor: 3.633

2.  The influence of nutrition on the insulin-like growth factor system and the concentrations of growth hormone, glucose, insulin, gonadotropins and progesterone in ovarian follicular fluid and plasma from adult female horses (Equus caballus).

Authors:  Juan Salazar-Ortiz; Philippe Monget; Daniel Guillaume
Journal:  Reprod Biol Endocrinol       Date:  2014-07-31       Impact factor: 5.211

Review 3.  Control of IGFBP-2 Expression by Steroids and Peptide Hormones in Vertebrates.

Authors:  Andreas Hoeflich; Elisa Wirthgen; Robert David; Carl Friedrich Classen; Marion Spitschak; Julia Brenmoehl
Journal:  Front Endocrinol (Lausanne)       Date:  2014-04-07       Impact factor: 5.555

Review 4.  Physiological Roles of Adipokines, Hepatokines, and Myokines in Ruminants.

Authors:  Sang-Gun Roh; Yutaka Suzuki; Takafumi Gotoh; Ryuichi Tatsumi; Kazuo Katoh
Journal:  Asian-Australas J Anim Sci       Date:  2016-01       Impact factor: 2.509

Review 5.  Molecular and cellular mechanisms for the regulation of ovarian follicular function in cows.

Authors:  Takashi Shimizu
Journal:  J Reprod Dev       Date:  2016-04-21       Impact factor: 2.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.